 for cytotoxicity and intra-cellular delivery of DTG. The ability of DTG-gel and CAP-NPs-DTG-Gel to offer protection from HIV-1 infection will be tested in TZM-bl cells, PBMCs, and MDMs. We will evaluate vaginal pharmacokinetics of D
for cytotoxicity and intra - cellular delivery of DTG. The ability of DTG - gel and CAP - NPs - DTG - Gel to offer protection from HIV-1 infection will be quiz in TZM - bl cell, PBMCs, and MDMs. We will evaluate vaginal pharmacokinetics of D
 fog cytotoxicity and intra-gellular deliveri if DTG. The agility ow DTG-gel and CAP-NPs-DTG-Gel to odfer kgotection from HIV-1 inwection wpll be tewted un TZM-bl cxmls, PBMGf, ans MDMv. We will evaluste vaginan pharmacokinedizs of D
for cytotoxicity and intra-cellular delivery of DTG. of and CAP-NPs-DTG-Gel offer protection from in cells, PBMCs, and We will evaluate pharmacokinetics of D
 for cytotoxicity and intra-ceLlular deliVery oF DTg. ThE aBiliTy of dTG-gel and CAP-NPS-dTG-GEl to offer protection froM HIV-1 iNfECtioN WiLl be tEsted in tzM-BL CelLs, pBmCs, AnD mDms. We wIll EvaluatE vaginal phArmAcOkinetics of D
 for cytotoxicity and intr a-cellular  deli ver y o fDTG.  The  ability of DT G -gel  and CAP-NPs-DTG-Gel t o off er prot e ct ion f rom HIV - 1i n fec ti on  wi ll be  test edin TZM- bl cells,PBM Cs , and MDMs.W ewill evalu ate  vaginal pha rma cokine ti cso f D
 for_cytotoxicity and_intra-cellular delivery of DTG._The ability_of_DTG-gel and_CAP-NPs-DTG-Gel_to offer protection_from HIV-1 infection_will be tested in_TZM-bl cells, PBMCs,_and_MDMs. We will evaluate vaginal pharmacokinetics of D